Incidence and Clinical Significance of Drug‐Induced Antibodies and Hemolytic Anemia Associated With Beta‐Lactam Antibiotics: A Prospective Cohort Study
Pharmacoepidemiology and Drug Safety · 2026
DOI: 10.1002/pds.70259 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2026. Verfasst von Li Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Transfusion Medicine, Sichuan University West China Hospital, Chengdu, China. Hauptthemen laut MEDLINE: Anemia, Hemolytic, beta Lactam Antibiotics, Anti-Bacterial Agents, Antibodies. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
Background
Drug‐induced immune hemolytic anemia (DIIHA), a rare complication of beta‐lactams, lacks population‐level data on subclinical antibody prevalence.
Objective
To quantify drug‐induced antibody incidence and hematologic impact in beta‐lactam‐treated patients.
Methods
Prospective cohort of 4040 patients receiving ceftriaxone, piperacillin/trizobactam, piperacillin/sulbactam 2:1 and piperacillin/tazobactam at a Chinese tertiary hospital (2020.1–2020.9). Antibodies were detected via immunoadsorption assays. The primary outcomes were changes in hemoglobin, bilirubin, and lactate dehydrogenase (LDH) levels.
Results
Antibody positivity occurred in 18.07% (730/4040), highest with piperacillin/sulbactam 2:1 (24.02% vs. 0.43% Ceftriaxone, p < 0.001). Seropositive patients had a significant hemoglobin decline (Δ = −5.00 g/L, 95% CI −6.2 to −3.8) and bilirubin elevation (Δ = +0.95 μmol/L, 95% CI +0.4 to +1.5), but only 0.2% (2/730) progressed to severe anemia. Subclinical hemolysis (LDH > 250 U/L) was prevalent (89.3%).
Conclusion
Beta‐lactams exhibit high asymptomatic antibody rates (18.07%) with minimal severe hemolysis risk (0.2%). Protocolized monitoring and HLA screening may optimize safety. This first large‐scale prospective cohort quantifies the underrecognized epidemic of subclinical antibody formation, challenging traditional pharmacovigilance frameworks that focus solely on overt hemolysis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Transfusion Medicine, Sichuan University West China Hospital, Chengdu, China.
ORCID-Profile: Li Wang
Zitieren
APA
Wang, L., Wang, L., Wei, Z., Huang, C., Qin, L., & Tan, B. (2026). Incidence and Clinical Significance of Drug‐Induced Antibodies and Hemolytic Anemia Associated With Beta‐Lactam Antibiotics: A Prospective Cohort Study. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70259
Vancouver
Wang L, Wang L, Wei Z, Huang C, Qin L, Tan B. Incidence and Clinical Significance of Drug‐Induced Antibodies and Hemolytic Anemia Associated With Beta‐Lactam Antibiotics: A Prospective Cohort Study. Pharmacoepidemiology and Drug Safety. 2026. doi:10.1002/pds.70259
BibTeX
@article{Wang2026,
author = {Wang, Li and Wang, Lixin and Wei, Zengzhen and Huang, Chunyan and Qin, Li and Tan, Bin},
title = {Incidence and Clinical Significance of Drug‐Induced Antibodies and Hemolytic Anemia Associated With Beta‐Lactam Antibiotics: A Prospective Cohort Study},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2026},
doi = {10.1002/pds.70259}
}
EUVIMED